Skip to content
Subscriber Only

Intercell, Merck Advised Not to Add Patients to Study

Merck & Co. and Intercell AG said a safety panel advised halting patient enrollment in a test of an experimental vaccine against a deadly hospital infection. Intercell slid 28 percent.

The vaccine, known as V710, aims to prevent infection caused by the Staphylococcus aureus bacteria. The independent data monitoring committee recommended the suspension while it weighs the benefits to the patients against the product’s risk, the companies said in a statement.